Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 10,358	$ 2,593
General and administrative	5,020	2,880
Acquired in-process research and development		164,612
Total operating expenses	15,378	170,085
Loss from operations	(15,378)	(170,085)
Other income (expense):
Interest and investment income	56	14
Other expense, net	(1)	(13)
Total other income, net	55	1
Net loss	$ (15,323)	$ (170,084)
Net loss per share - basic	$ (1.18)	$ (45.60)
Net loss per share - diluted	$ (1.18)	$ (45.60)
Weighted-average common shares outstanding used in net loss per share - basic	13,016,955	3,730,029
Weighted-average common shares outstanding used in net loss per share - diluted	13,016,955	3,730,029